바이오 제조용 바이탈 프로틴 시장 : 그룹, 기능, 적응증별 - 세계 예측(2025-2030년)

The Vital Proteins for Biomanufacturing Market was valued at USD 52.10 billion in 2023, expected to reach USD 56.52 billion in 2024, and is projected to grow at a CAGR of 8.92%, to USD 94.81 billion by 2030.

Vital proteins in biomanufacturing serve as essential components in the production and development of therapeutic proteins, enzymes, and other biochemical products. Their scope includes applications in pharmaceuticals, biotechnology, and therapeutic manufacturing, where they facilitate processes like cell culture, protein purification, and formulation, crucial for producing monoclonal antibodies, vaccines, and recombinant proteins. The necessity of these proteins stems from their ability to enhance efficiency, yield, and quality of bio-based products, underscoring their indispensable role in modern biotechnological processes. End-use sectors primarily include pharmaceutical companies, research institutes, and biotech firms focusing on drug development and life sciences research. The market is driven by key factors such as increased demand for biologic drugs, advancements in protein engineering, and a surge in investment in biotechnological research and development. The growing adoption of sustainable and efficient bioprocesses highlights opportunities, particularly in personalized medicine and regenerative therapies. Companies can leverage these opportunities by focusing on innovative protein solutions that enhance bioprocess efficiency. However, the market faces challenges like high production costs, regulatory barriers, and the complexity of protein manufacturing, which can impede growth. Limited scalability and technical difficulties in protein production also present significant hurdles. For business growth, areas of innovation include developing cost-effective protein production technologies, improving methods of protein stabilization and storage, and creating novel applications for vital proteins in emerging biotechnologies. Additionally, partnerships with academic and research institutions can spur collaborative innovation, offering competitive advantages. The market is characterized by rapid technological advancements and a strong emphasis on sustainability and efficiency, indicating a dynamic environment with significant potential for growth. Companies can stay competitive by investing in research and harnessing cutting-edge technologies to meet the evolving demands of the biomanufacturing sector.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Vital Proteins for Biomanufacturing Market

The Vital Proteins for Biomanufacturing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing demand for biopharmaceuticals with enhanced therapeutic efficacy
  • Rapid adoption of novel cell culture platforms to produce complex biotherapeutics
  • Growing interest in personalized medicine necessitates tailored protein therapeutics
• Market Restraints
  • High capital expenditure requirements for establishing state-of-the-art biomanufacturing facilities
• Market Opportunities
  • Supportive government policies promoting investments in research & development
  • Ongoing collaborations between academia & industry players for technological innovations in vital proteins
• Market Challenges
  • Complexities associated with scaling up production processes

Porter's Five Forces: A Strategic Tool for Navigating the Vital Proteins for Biomanufacturing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Vital Proteins for Biomanufacturing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Vital Proteins for Biomanufacturing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Vital Proteins for Biomanufacturing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Vital Proteins for Biomanufacturing Market

A detailed market share analysis in the Vital Proteins for Biomanufacturing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Vital Proteins for Biomanufacturing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Vital Proteins for Biomanufacturing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Vital Proteins for Biomanufacturing Market

A strategic analysis of the Vital Proteins for Biomanufacturing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Vital Proteins for Biomanufacturing Market, highlighting leading vendors and their innovative profiles. These include Abcam PLC, Abnova Corporation, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., BioLegend, Inc. by PerkinElmer, Inc., Biologics International Corporation, BPS Bioscience, Inc., Bristol-Myers Squibb Company, Creative BioMart Inc., Croyez Bioscience Co., Ltd., Eli Lilly and Company, Enzo Life Sciences, Inc., GenScript Biotech Corporation, Johnson & Johnson Services, Inc., Laurus Bio Private Limited, LenioBio GmbH, Lonza Group AG, Merck KGaA, Meridian Bioscience, Inc. by SD Biosensor Inc., Miltenyi Biotec B.V. & Co. KG, Novartis AG, ProMab Biotechnologies, Inc., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Vital Proteins for Biomanufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Groups, market is studied across Cytokines, Enzymes & Chemicals, Expression Systems, Media & Supplements, Protein A Resins, Quality Control Reagents, and Vectors & Transfection Reagents. The Cytokines is further studied across Chemokines, Colony-stimulating factors, Interferons, Interleukins, and Tumor necrosis factors. The Enzymes & Chemicals is further studied across DNA Capping Enzymes, Endonucleases, Glycosidases, Polyadenylation Enzymes, Protease Inhibitors, and Transcription Enzymes. The Expression Systems is further studied across Bacterial, Insect, Mammalian Cells, and Yeast. The Media & Supplements is further studied across Albumin, Epidermal Growth Factor (EGF), Fibroblast Growth Factors (FGFs), Insulin-like Growth Factors (IGFs), Transferrin, and Vascular Endothelial Growth Factor (VEGF).
• Based on Function, market is studied across Diagnostics and Drug Discovery & Development. The Drug Discovery & Development is further studied across Biologics, Cell & Gene Therapy, and Vaccines.
• Based on Indication, market is studied across Autoimmune Disorders, Infectious Diseases, Oncology, and Rare Genetic Disorders.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing demand for biopharmaceuticals with enhanced therapeutic efficacy
    • 5.1.1.2. Rapid adoption of novel cell culture platforms to produce complex biotherapeutics
    • 5.1.1.3. Growing interest in personalized medicine necessitates tailored protein therapeutics
  • 5.1.2. Restraints
    • 5.1.2.1. High capital expenditure requirements for establishing state-of-the-art biomanufacturing facilities
  • 5.1.3. Opportunities
    • 5.1.3.1. Supportive government policies promoting investments in research & development
    • 5.1.3.2. Ongoing collaborations between academia & industry players for technological innovations in vital proteins
  • 5.1.4. Challenges
    • 5.1.4.1. Complexities associated with scaling up production processes
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Vital Proteins for Biomanufacturing Market, by Groups

• 6.1. Introduction
• 6.2. Cytokines
  • 6.2.1. Chemokines
  • 6.2.2. Colony-stimulating factors
  • 6.2.3. Interferons
  • 6.2.4. Interleukins
  • 6.2.5. Tumor necrosis factors
• 6.3. Enzymes & Chemicals
  • 6.3.1. DNA Capping Enzymes
  • 6.3.2. Endonucleases
  • 6.3.3. Glycosidases
  • 6.3.4. Polyadenylation Enzymes
  • 6.3.5. Protease Inhibitors
  • 6.3.6. Transcription Enzymes
• 6.4. Expression Systems
  • 6.4.1. Bacterial
  • 6.4.2. Insect
  • 6.4.3. Mammalian Cells
  • 6.4.4. Yeast
• 6.5. Media & Supplements
  • 6.5.1. Albumin
  • 6.5.2. Epidermal Growth Factor (EGF)
  • 6.5.3. Fibroblast Growth Factors (FGFs)
  • 6.5.4. Insulin-like Growth Factors (IGFs)
  • 6.5.5. Transferrin
  • 6.5.6. Vascular Endothelial Growth Factor (VEGF)
• 6.6. Protein A Resins
• 6.7. Quality Control Reagents
• 6.8. Vectors & Transfection Reagents

7. Vital Proteins for Biomanufacturing Market, by Function

• 7.1. Introduction
• 7.2. Diagnostics
• 7.3. Drug Discovery & Development
  • 7.3.1. Biologics
  • 7.3.2. Cell & Gene Therapy
  • 7.3.3. Vaccines

8. Vital Proteins for Biomanufacturing Market, by Indication

• 8.1. Introduction
• 8.2. Autoimmune Disorders
• 8.3. Infectious Diseases
• 8.4. Oncology
• 8.5. Rare Genetic Disorders

9. Americas Vital Proteins for Biomanufacturing Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Vital Proteins for Biomanufacturing Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Vital Proteins for Biomanufacturing Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. New England Biolabs Introduces Faustovirus Capping Enzyme, a Novel Enzymatic mRNA Capping Solution for mRNA Manufacturing
  • 12.3.2. Everest Medicines Ltd. acquires rights to 3C-like protease inhibitors to develop antivirals for COVID-19
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abcam PLC
• 2. Abnova Corporation
• 3. Agilent Technologies, Inc.
• 4. Bio-Rad Laboratories, Inc.
• 5. BioLegend, Inc. by PerkinElmer, Inc.
• 6. Biologics International Corporation
• 7. BPS Bioscience, Inc.
• 8. Bristol-Myers Squibb Company
• 9. Creative BioMart Inc.
• 10. Croyez Bioscience Co., Ltd.
• 11. Eli Lilly and Company
• 12. Enzo Life Sciences, Inc.
• 13. GenScript Biotech Corporation
• 14. Johnson & Johnson Services, Inc.
• 15. Laurus Bio Private Limited
• 16. LenioBio GmbH
• 17. Lonza Group AG
• 18. Merck KGaA
• 19. Meridian Bioscience, Inc. by SD Biosensor Inc.
• 20. Miltenyi Biotec B.V. & Co. KG
• 21. Novartis AG
• 22. ProMab Biotechnologies, Inc.
• 23. Thermo Fisher Scientific Inc.